JANX Q1 2022 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+318.2% YoY

Gross Profit

-$9M-540.9% margin

Operating Income

-$14M-852.2% margin

Net Income

-$13M-843.9% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$369M

Total Liabilities

$13M

Stockholders' Equity

$356M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$380,000	+318.2%
Gross Profit	-$9M	-$2M	-456.3%
Operating Income	-$14M	-$2M	-492.9%
Net Income	-$13M	-$2M	-487.1%